Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHASTA-5 phase 3 study of plozasiran in adults with severe hypertriglyceridemia at high risk for acute pancreatitis
MOH_2026-05-17_015823Phase 3Recruiting
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Feb 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertriglyceridemia comparing Redemplo with Placebo (2 arms). Started Feb 2026; status: recruiting.
02
Drugs
plozasiran
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on MOH_2026-05-17_015823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-05-17_015823.